A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
Trial details
- Registry ID
- NCT07157254
- Phase
- Phase 2
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)NCT07157254 | RARE | Phase 2 | Terminated | 2026-10-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |